With plans to enable genomic surveillance for antimicrobial resistant pathogens using Ares’ next-generation sequencing and bioinformatics technologies, the OpGen subsidiary and Sandoz have shaken hands on an extension to their initial master services agreement.
Sandoz has extended until 31 January 2025 its existing master services agreement with Ares Genetics “to drive cutting-edge digital solutions in the global fight against antimicrobial resistance,” ahead of the next phase of the collaboration.
The parties had teamed up more than three years ago, in December 2018, to jointly develop a digital anti-infectives platform...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
